Customizing inhaled therapy to meet the needs of COPD patients
- PMID: 20203459
- DOI: 10.3810/pgm.2010.03.2125
Customizing inhaled therapy to meet the needs of COPD patients
Abstract
Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by airflow limitation resulting from emphysema and chronic bronchitis. Inhaled therapy is the major therapeutic approach for treating COPD. Multiple inhaler medications are available in the United States and are delivered by a variety of different devices: metered-dose inhalers, dry powdered inhalers, and nebulizers. Each inhaler device has unique requirements for use that must be correctly performed by the patient for successful drug delivery. Patients with COPD represent a medically diverse population, with each patient having distinct characteristics, such as lung function, comorbidities, cognitive functions, hand strength, and lifestyle. These characteristics impact the patient's ability to properly use specific inhaler devices and therefore affect adherence to therapy, therapeutic outcomes, and quality of life. It is estimated that between 28% to 68% of patients do not use metered-dose inhalers or dry powder inhalers correctly. Worsening symptoms or increased frequency of exacerbations may not always indicate disease progression but may indicate a patient's inability to use their inhaler device properly. This review discusses the patient- and device-specific factors to be considered when choosing an inhaled therapy, which will be concordant with the patient's medical needs, preferences, and lifestyle. The review also considers how the ideas underlying the patient-centered medical home model can be incorporated into the choice and use of inhaler device for a given patient with COPD to improve treatment outcomes.
Similar articles
-
Inhalatory therapy training: a priority challenge for the physician.Acta Biomed. 2007 Dec;78(3):233-45. Acta Biomed. 2007. PMID: 18330086 Review.
-
Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.Respir Care. 2005 Oct;50(10):1313-21; discussion 1321-2. Respir Care. 2005. PMID: 16185367 Review.
-
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.Respir Med. 2007 Dec;101(12):2464-71. doi: 10.1016/j.rmed.2007.07.006. Epub 2007 Aug 24. Respir Med. 2007. PMID: 17719763 Clinical Trial.
-
Inhaler devices for patients with COPD.COPD. 2013 Aug;10(4):523-35. doi: 10.3109/15412555.2012.761960. Epub 2013 Mar 28. COPD. 2013. PMID: 23537191 Review.
-
Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide.Respir Med. 2005 Jul;99(7):836-49. doi: 10.1016/j.rmed.2005.02.012. Epub 2005 Mar 23. Respir Med. 2005. PMID: 15939245 Review.
Cited by
-
Perceptions and Attitudes of Patients and Their Family Caregivers on Nebulization Therapy for COPD.Int J Chron Obstruct Pulmon Dis. 2022 Sep 14;17:2277-2288. doi: 10.2147/COPD.S367819. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 36133736 Free PMC article.
-
Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers.Pharmaceuticals (Basel). 2022 Mar 23;15(4):389. doi: 10.3390/ph15040389. Pharmaceuticals (Basel). 2022. PMID: 35455386 Free PMC article.
-
Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home.Int J Chron Obstruct Pulmon Dis. 2021 Sep 28;16:2687-2695. doi: 10.2147/COPD.S332021. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 34611397 Free PMC article. Review.
-
Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol.Patient Prefer Adherence. 2018 Jun 8;12:993-1001. doi: 10.2147/PPA.S152179. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 29922045 Free PMC article. Review.
-
Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial.Int J Chron Obstruct Pulmon Dis. 2016 Nov 22;11:2859-2867. doi: 10.2147/COPD.S119114. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27920513 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical